Clinical Barriers in Treating Patients with Schizophrenia Who Use Cannabis
DOI:
https://doi.org/10.47611/jsrhs.v12i1.3242Keywords:
Schizophrenia, Cannabis, Marijuana, Psychosis, Psychotic Disorders, Addiction Psychology, Psychiatry, Emerging Fields, Clinics, PsychologyAbstract
Within the past two decades, psychiatric clinics have seen an increase in the number of patients with schizophrenia who use cannabis. Studies have demonstrated the drug’s exacerbating effects on schizophrenia symptoms and treatment, posing a challenge to clinicians who treat this patient population. However, insight into the perspectives and needs of these clinicians remains largely absent within the existing literature. To provide them a voice, this study utilized surveying and interviewing with a mixed quantitative and qualitative design to evaluate and analyze the perspectives, concerns, and needs of clinicians who treat patients with schizophrenia who use cannabis. Participating clinicians (n = 5) were generally confident in understanding how cannabis use affects schizophrenia and their roles as providers. However, these clinicians were less confident in the effectiveness of existing treatments, education, and literature on the subject. Additionally, participants voiced concerns about issues such as the limitations of existing literature on this patient population, the lack of established guidelines and protocols for treating this patient population, and the absence of educational resources and materials for both clinicians and patients. Overall, the number of voiced concerns and the high variation between clinicians strongly imply the necessity of these clinicians’ perspectives within research on this patient population. Increased involvement of medical professionals within the literature on cannabis use in schizophrenia should hopefully serve to implement and improve the resources that these clinicians need to make a lasting positive change in patients with schizophrenia who use cannabis.
Downloads
References or Bibliography
Addington, J., & Duchak, V. (1997). Reasons for substance use in schizophrenia. Acta Psychiatrica Scandinavica, 96(5), 329-333. https://doi.org/10.1111/j.1600-0447.1997.tb09925.x
American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders: DSM-V (5th edition). American Psychiatric Publishing. https://doi.org/10.1176/appi.books.9780890425596.
Ascher-Svanum, H., Fairies, D., Zhu B., Ernst, F., Swartz, M., & Swanson, J. (2006). Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. Journal of Clinical Psychiatry, 67, 453-460. https://doi.org/10.4088/jcp.v67n0715.
Awad, A. G., & Voruganti, L. L. N. P. (2015). Revisiting the ‘self-medication’ hypothesis in light of the new data linking low striatal dopamine to comorbid addictive behavior. Therapeutic Advances in Psychopharmacology, 5(3), 172-178. https://doi.org/10.1177/2045125315583820.
Burns, J. K. (2013). Pathways from Cannabis to Psychosis: A Review of the Evidence. Frontiers in Psychiatry, 4(128), 1-12. https://doi.org/10.3389/fpsyt.2013.00128.
Dixon, L. (1999). Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophrenia Research, 35(1), 93-100. https://doi.org/10.1016/s0920-9964(98)00161-3.
D’Souza, D. C., Abi-Saab, W. M., Madonick, S., Forselius-Bielen, K., Doersch, A., Braley, G., Gueorguieva, R., Cooper, T. B., & Krystal, J. H. (2005). Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biological Psychiatry, 57(6), 594-608. https://doi.org/10.1016/j.biopsych.2004.12.006.
Hides, L., Dawe, S., Kavanagh, D., & Young, R. (2006). Psychotic symptom and cannabis relapse in recent-onset psychosis. British Journal of Psychiatry, 189(2), 137-143. https://doi.org/10.1192/bjp.bp.105.014308.
Higashi, K., Medic, G., Littlewood, K. J., Diez, T., Granstrom, O., & Hert, M. D. (2013). Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Therapeutic Advances in Psychopharmacology, 3(4), 200-218. https://doi.org/10.1177/2045125312474019.
Hjorthøj, C., Fohlmann, A., & Nordentoft, M. (2009). Treatment of cannabis use disorders in people with schizophrenia spectrum disorders – a systematic review. Addictive Behaviors, 34(6-7), 520-525. https://doi.org/10.1016/j.addbeh.2009.02.001.
Hjorthøj, C., Larsen, M. O., Starzer, M. S. K., & Nordentoft, M. (2019). Annual incidence of cannabis-induced psychosis, other substance-induced psychoses, and dually diagnosed schizophrenia and cannabis use disorder in Denmark from 1994 to 2016. Psychological Medicine, 51(4), 617-622. https://doi.org/10.1017/s0033291719003532.
Jager, G., Block, R. I., Luijten, M., & Ramsey, N. F. (2010). Cannabis Use and Memory Brain Function in Adolescent Boys: A Cross-Sectional Multicenter Functional Magnetic Resonance Imaging Study. Journal of the American Academy of Child & Adolescent Psychiatry, 49(6), 561-572. https://doi.org/10.1016/j.jaac.2010.02.001.
Janssen, B., Gaebel, W., Haerter, M., Komaharadi, F., Lindel, B., Weinmann, S. (2006). Evaluation of factors influencing medication compliance in inpatient treatment of psychotic disorders. Psychopharmacology, 187(2), 229-236. https://doi.org/10.1007/s00213-006-0413-4.
Khantzian, E. J. (1985). The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. American Journal of Psychiatry, 142(11), 1259-1264. https://doi.org/10.1176/ajp.142.11.1259
Khantzian, E. J. (1997). The self-medication hypothesis of substance use disorders: a reconsideration and recent applications. Harvard Review of Psychiatry, 4(5), 231-244. https://doi.org/10.3109/10673229709030550.
Khokhar, J. Y., Dwiel, L., Henricks, A., Doucette, W. T., & Green, A. I. (2018). The Link Between Schizophrenia and Substance Use Disorder: A Unifying Hypothesis. Schizophrenia Research, 194, 78-85. https://doi.org/10.1016/j.schres.2017.04.016.
Lacro, J. P., Dunn, L. B., Dolder, C. R., Leckband, S. G., & Jeste, D. V. (2002). Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. Journal of Clinical Psychiatry, 63(10), 892-909. https://doi.org/10.4088/jcp.v63n1007.
Mane, A., Fernandez-Exposito, M., Berge, D., Gomez-Perez, L., Sabate, A., Toll, A., Diaz, L., Diez-Aja, C., & Perez, V. (2015). Relationship between cannabis and psychosis: Reasons for use and associated clinical variables. Psychiatry Research, 229(1-2), 70-74. https://doi.org/10.1016/j.psychres.2015.07.070.
Novick, D., Haro, J. M., Suarez, D., Perez, V., Dittmann, R. W., & Haddad, P. M. (2010). Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Research, 176(2-3), 109-113. https://doi.org/10.1016/j.psychres.2009.05.004.
Regier, D. A., Myers, J. K., Kramer, M., Robins, L. N., Blazer, D. G., Hough, R. L., Eaton, W. W., & Locke, B. Z. (1984). The NIMH Epidemiologic Catchment Area program. Historical context, major objectives, and study population characteristics. JAMA Psychiatry, 41(10), 934-941. https://doi.org/10.1001/archpsyc.1984.01790210016003.
Rosen, C. S., Kuhn, E., Greenbaum, M. A., Drescher, K. D. (2008). Substance-Abuse Related Mortality Among Middle-Aged Male VA Psychiatric Patients. Psychiatric Services, 59(3), 290-296. https://doi.org/10.1176/ps.2008.59.3.290.
Schoeler, T., Petros, N., Di Forti, M., Pingault, J., Klamerus, E., Foglia, E., Small, A., Murray, R., & Bhattacharyya, S. (2016). Association between continued cannabis use and risk of relapse in first-episode psychosis: A Quasi-Experimental Investigation Within an Observational Study. JAMA Psychiatry, 73(11), 1173-9. https://doi.org/10.1001/jamapsychiatry.2016.2427.
Schultz, B. R., Rodriguez-Cabezas, L., Angres, D., & Smith, M. J. (2015). Treatment strategies for cannabis use in schizophrenia. Current Treatment Options in Psychiatry, 2, 168-181. https://doi.org/10.1007/s40501-015-0043-8.
Shrivastava, A., Johnston, M., Terpstra, K., & Bureau, Y. (2014). Cannabis and psychosis: Neurobiology. Indian Journal of Psychiatry, 56(1), 8-16. https://doi.org/10.4103/0019-5545.124708.
Solowij, N., & Michie, P. T. (2007). Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia. Journal of Psychiatry and Neuroscience, 32(1), 30-52. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1764544/.
Svarstad, B. L., Shireman, T. I., & Sweeney, J. K. (2001). Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatric Services, 52(6), 805-811. https://doi.org/10.1176/appi.ps.52.6.805.
Swofford, C. D., Kasckow, J. W., Scheller-Gilkey, G., & Inderbitzin, L. B. (1996). Substance use: a powerful predictor of relapse in schizophrenia. Schizophrenia Research, 20(1-2), 145-151. https://doi.org/10.1016/0920-9964(95)00068-2.
Valenstein, M., Copeland, L. A., Blow, F. C., McCarthy, J. F., Zeber, J. E., Gillon, L., Bingham, C. R., & Stavenger, T. (2002). Pharmacy Data Identify Poorly Adherent Patients With Schizophrenia at Increased Risk for Admission. Medical Care, 40(8), 630-639. https://doi.org/10.1097/00005650-200208000-00002.
Weiden, P., Kozma, C., Grogg, A., & Locklear, J. (2004). Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatric Services, 55(8), 886-891. https://doi.org/10.1176/appi.ps.55.8.886.
Published
How to Cite
Issue
Section
Copyright (c) 2023 Maxwell Igwe; Brandon Vanbibber
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright holder(s) granted JSR a perpetual, non-exclusive license to distriute & display this article.
